Related references
Note: Only part of the references are listed.Low serum level of hepatitis B indicates unlikely reactivation core-related antigen of hepatitis after cessation of lamivudine therapy
Akihiro Matsumoto et al.
HEPATOLOGY RESEARCH (2007)
Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine
Tsuyoshi Hatakeyama et al.
HEPATOLOGY (2007)
Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance
Yasuji Arase et al.
INTERVIROLOGY (2007)
Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection
Noboru Shinkai et al.
HEPATOLOGY RESEARCH (2006)
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C
Mariko Kobayashi et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
Chee-Kin Hui et al.
GASTROENTEROLOGY (2006)
Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance
E Tanaka et al.
LIVER INTERNATIONAL (2006)
Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy
Akinori Rokuhara et al.
JOURNAL OF GASTROENTEROLOGY (2006)
Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection
A Rokuhara et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain
T Kimura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy
JJY Sung et al.
GASTROENTEROLOGY (2005)
Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection
MF Yuen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Chronic hepatitis B: Update of recommendations
ASF Lok et al.
HEPATOLOGY (2004)
Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment
A Rokuhara et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
F Suzuki et al.
INTERVIROLOGY (2003)
Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load
T Kimura et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
RJ Colonno et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil
R Chin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
